[Post-menopausal osteoporosis: Up-to-date].
1Service de rhumatologie, hôpital Cochin, université Paris-Descartes, Inserm U 1153, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
La Revue De Medecine Interne
|January 3, 2016
Summary
High-risk patients need immediate anti-osteoporotic treatment for fragility fractures. Treatment duration depends on individual fracture risk assessment.
Area of Science:
- Orthopedics
- Geriatrics
- Pharmacology
Background:
- Osteoporosis poses a significant risk for fragility fractures.
- Fractures of the hip, vertebrae, pelvis, and humerus have severe consequences.
Purpose of the Study:
- To emphasize the priority of anti-osteoporotic treatment for high-risk patients.
- To outline the recommended treatment modalities and duration.
Main Methods:
- Prioritization of patients based on fracture risk and recent fracture history.
- Integration of non-pharmacological and pharmacological treatment strategies.
- Individualized treatment duration based on ongoing fracture risk assessment.
Main Results:
- High-risk patients with fragility fractures require immediate intervention.
- A combination of non-pharmacological and pharmacological treatments is essential.
- Treatment duration should be tailored to the patient's evolving fracture risk.
Conclusions:
- Prompt initiation of anti-osteoporotic therapy is crucial for patients at high risk of fragility fractures.
- Comprehensive treatment plans including lifestyle modifications and medication are necessary.
- Ongoing assessment of fracture risk guides the duration of anti-osteoporotic treatment.
Related Concept Videos
01:28Menopause
5.1K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.1K
01:29Bone Disorders
7.4K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
7.4K
01:40Bone Remodeling
41.0K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
41.0K
01:31Osteoclasts in Bone Remodeling
4.7K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.7K
01:22Hormonal Regulation of the Menstrual Cycle
2.3K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.3K
02:07Oogenesis
71.3K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
71.3K